Press release
MeiraGTx Announces the Presentation of Nine Posters at the American Society of Gene and Cell Therapy (ASGCT) 2023 Annual Meeting
Multiple Poster Presentations Highlight the Depth and Novelty of MeiraGTx’s Technology Platforms for Gene and Cell Therapy LONDON and NEW YORK, May 16, 2023
About this update from Meiragtx Holdings Plc
[{"type":"text","content":"Multiple Poster Presentations Highlight the Depth and Novelty of MeiraGTx’s Technology Platforms for Gene and Cell Therapy\nLONDON and NEW YORK, May 16, 2023 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced the Company will exhibit nine poster presentations at the American Society of Gene and Cell Therapy (ASGCT) 2023 Annual Meeting, which is being held from May 16-20, 2023, in Los Angeles, CA. “Our presentations at this year’s ASGCT Annual Meeting reflect the significant progress made in our novel gene and cell therapy platforms, including promoter discovery and development, manufacturing technology as well as several in vivo proof of concept efficacy studies using our riboswitch platform,” said Alexandria Forbes, Ph.D., president and chief executive officer of MeiraGTx. “Our riboswitch gene control platform allows us to precisely control the expression of any gene in a tight dose response to oral small molecules and to control gene expression to a very high dynamic range, from undetectable at baseline to levels generally greater than the maximum expression of the unregulated vector expressing the same gene. Importantly, we are presenting data on in vivo dose dependent efficacy of our riboswitch in animal models. We demonstrate efficacy of vector-delivered human growth hormone, rescuing B.little mice by controlling hGH expression in a periodic fashion with an oral small molecule, and data demonstrating control of tumor burden by regulating anti-HER2 antibody in tight dose response to an orally dosed small-molecule inducer.” Dr. Forbes continued, “We are also presenting data demonstrating precise regulation of CAR levels on CAR-Ts, with the unprecedented ability to intermittently switch CAR on to low receptor density levels, which results in increased CAR-T potency, decreased exhaustion markers and increased safety when directly compared to CAR-T with constitutively expressed CAR. These three examples, along with data on our promoter discovery platforms presented at ASGCT, provide support for the broad applicability of our gene regulation technology across multiple therapeutic targets for gene and cell therapy.” The posters will be available on the Posters and Publications page of the Company’s website after the respective presentation session...